Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Repligen to initiate Phase IIb bipolar disorder study
This will be a multi-center, parallel arm placebo-controlled, clinical trial in which approximately 150 patients with bipolar disorder will receive either RG2417 or a placebo twice a day
This will be a multi-center, parallel arm placebo-controlled, clinical trial in which approximately 150 patients with bipolar disorder will receive either RG2417 or a placebo twice a day
The trial will be an open-label, Phase II study of IT-101 intended to demonstrate safety and efficacy in patients with relapsed or refractory lymphoma, and will be preceded
The test is designed with a dual target approach to help ensure reliability of test results even when mutations occur in the bacteria’s cryptic plasmid DNA. The highly
Today Sponge is constructed of soft polyurethane foam containing a well-known, locally acting, non-systemic spermicide, N-9, the company said. The manufacturing process involves both sponge creation and active
The combined company will have a major presence in key growth markets and exceptional technical capabilities in the areas of genetic analysis, proteomics, cell biology and cell systems.
The Indian Drug Manufacturers Association (IDMA) has requested the drug price regulator to increase the prices of bulk drugs citing the depreciation in rupee value and hike in
Patients with acute lymphoblastic leukemia (ALL) are initially treated with complex and highly toxic chemotherapy regimens, which may be followed by bone marrow stem cell transplantation for eligible
Itero and Biological E will collaborate to obtain worldwide approvals and commercialize jointly developed biopharmaceuticals. Itero will be responsible for financing the development of the drug candidates, while
Dr Cone has accepted the position of chairman of the department of molecular physiology and biophysics at Vanderbilt University Medical Center, starting in August, but will continue as
The patent grants EntreMed composition-of-matter and method of use intellectual property protection through 2025 for analogs of 2- methoxyestradiol (2ME2) in oncology and a broad range of non-oncology